Loading
A phase 1/2 trial of Daraxonrasib, Bevacizumab, Cetuximab in colorectal cancer and pancreatic ductal adenocarcinoma, run by Revolution Medicines, Inc., now recruiting.
Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors is a phase 1/2 interventional study registered as NCT06445062 by Revolution Medicines, Inc., with 1130 participants planned, started 2024-05-24 and due to reach its primary completion in 2027-05-15. Interventions recorded: RMC-6236, mFOLFOX6 regimen, bevacizumab, mFOLFIRINOX regimen, cetuximab. Conditions listed: Colorectal Cancer, CRC, Pancreatic Ductal Adenocarcinoma, PDAC. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Zoldonrasib, Revolution Medicines, Daraxonrasib, Paclitaxel / nab-paclitaxel.
Shares Zoldonrasib, Revolution Medicines, Daraxonrasib, Pancreatic ductal adenocarcinoma.
Shares Zoldonrasib, Daraxonrasib, Paclitaxel / nab-paclitaxel, Gemcitabine.
Shares Cetuximab, Paclitaxel / nab-paclitaxel, Gemcitabine, Pancreatic ductal adenocarcinoma.
Shares Zoldonrasib, Revolution Medicines, Daraxonrasib, Colorectal cancer.
Shares Revolution Medicines, Daraxonrasib, Pancreatic ductal adenocarcinoma, Colorectal cancer.
Shares Revolution Medicines, Daraxonrasib, Pancreatic ductal adenocarcinoma, Colorectal cancer.
Shares Zoldonrasib, Daraxonrasib, Pancreatic ductal adenocarcinoma.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/